Sentences with phrase «including generic drugs»

But health care analysts say the coupons may also discourage patients from considering appropriate lower - cost alternatives, including generic drugs.

Not exact matches

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

Other pain points included drug pricing and how approving more generics may affect costs (Gottlieb parried that question by noting the FDA doesn't have the authority to negotiate prices or consider pricing when approving a drug) and his alleged softness on opioid drug makers due the aforementioned financial ties and pro-industry ideology (the nominee noted that he considers opioid addiction and overdoses a public health crisis «on the order of Ebola and Zika»).

Jean Coutu has a network of 417 franchised stores in Quebec, New Brunswick and Ontario under several banners including PJC Jean Coutu as well as a subsidiary that makes generic drugs.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

A solid performance from new Hep - C drug ZEPATIER and a double - digit increase in animal health sales (+13 %) further bolstered results, helping to offset generic pressures on several off - patent drugs, including ZETIA / VYTORIN -LRB--35 %), REMICADE -LRB--34 %), CUBICIN -LRB--67 %), and NASONEX -LRB--40 %).

The FDA's action cuts off a vital supply line for the company, given that the plant reportedly makes about 70 % of the ingredients that Ranbaxy uses to make its U.S. drugs, including the generic version of Lipitor taken by millions of Americans.

The generic drug maker has hired Morgan Stanley to review available options, including an acquisition or sale of the company.

The solanezumab disappointment comes at a time when Lilly is facing generic competition on several high - profile drugs, including erectile dysfunction medicine Cialis, ADHD drug Strattera and cardiovascular treatment Effient.

A federal judge in Delaware on Friday struck down key patents held by Acorda related to Ampyra, opening the doors for generic versions of the drug by companies including Mylan Inc (MYL.O) and Roxane Laboratories Inc..

«A civil war has broken out among the most powerful players in the pharmaceutical industry — including brand - name and generic drug makers, and even your local pharmacists — with each blaming others for the rising price of medicine.»

These include patent expirations, the rise of competition from generics, a downward pressure on drug prices, increasing scrutiny from regulators and health technology assessment bodies, pressure to move research offshore, and the crisis in R&D productivity.

Although most of the shortages affect old, generic drugs, clinical trials often use these staples, either as controls or in combination with experimental medicines, including the genetically targeted drugs that many hope will revolutionize cancer care.

But as its patent expires on November 30 and its first generic competitor takes the stage, Lipitor is also a painful reminder of the challenge that such «patent cliffs» pose for the big drug companies, including Lipitor's developer Pfizer, based in New York.

The study included 35 patients, adults with epilepsy who currently take lamotrigine, and looked at long - term dosing using two currently on - market epileptic generic drugs.

The generic risperidone products will have the same safety warnings as Risperdal, including a boxed warning, cautioning that older patients with dementia - related psychosis treated with atypical anti-psychotic drugs are at increased risk of death, as compared with those taking placebo.

Its researchers made ground - breaking discoveries, including the findings that calorie - burning brown fat may remain active in adults and that the generic drug salsalate is a promising treatment for people with type 2 diabetes.

Plan includes pharmacy benefit with coverage for generic, preferred brand and non-preferred brand drugs as well as a mail order drug program.

MORE THAN 2 MILLION More than 2 million prescriptions each year are written in the United States for natural desiccated thyroid drugs — including Armour Thyroid, Nature - throid, WP Thyroid, and the Acella - made generic natural thyroid drug.

Examples of Medicaid fraud include: billing for services not performed, providing unnecessary services, billing for more expensive services, billing for services separately that should legitimately be one billing, billing more than once for the same medical service, dispensing generic drugs but billing for brand name drugs.

Examples include the 2015 acquisitions of Cordis (a manufacturer and distributor of interventional cardiology devices and endovascular solutions) and Harvard Drug (a distributor of generic and over-the-counter drugs); the 2013 acquisition of AssuraMed (distributor of home health care products); and the 2010 acquisitions of Kinray (distributor to independent pharmacies) and Yong Yu (a leading distributor in China).

This site offers a «medic alert» type collar tag for MDR1 dogs and has more extensive list, including alternate and generic names for the drugs:

We're the United States» oldest wholesale distributor of veterinary supplies, including a wide range of generic drugs, equipment and food.

Like many drugs, there are a number of names by which Clomipramine can go by, including Anafanil (made by Novartis,) Clomicalm (manufactured by Novartis) or the generic Clomipramine Hydrochloride.

Dr. Hill's work has included serving as trial counsel for plaintiffs and defendants in patent infringement suits involving breast and ovarian cancer gene tests, radiology informatics, hospital information systems, orthopedic surgical devices, MRI diffusion tensor imaging, generic drugs in Hatch - Waxman patent litigation, and biologics in suits brought under the Biologics Price Competition and Innovation Act.

In other generic drug injury news, the U.S. Food and Drug Administration has suggested a new rule that would allow manufacturers of generic meds to independently include new side effect information to the labels of their medicatdrug injury news, the U.S. Food and Drug Administration has suggested a new rule that would allow manufacturers of generic meds to independently include new side effect information to the labels of their medicatDrug Administration has suggested a new rule that would allow manufacturers of generic meds to independently include new side effect information to the labels of their medication.

The Jean Coutu Group were facing several challenges at the time including drug distribution reform and the purchase of a Quebec generic drug manufacturer.

Types of medications (including the names of generic and brand drugs) that have been linked to Stevens - Johnson Syndrome: • Anticonvulsants • Antibiotics • Nonsteroidal anti-inflammatory drugs (OTC and prescription) • Drugs with sulfa • Barbiturates • COX - 2 inhibitors • Ibuprofen • Acetaminophens • Allopurinol • Carbamazepine • Phenytoin • Bextra, which Pfizer removed from the market in 2005 because of the SJS risk it posed to users • Children's Advil or Motrin • Tylenol • Aldactone • Septra • Advil • Motrin • Avelox • Prilosec • Neurontin • Coreg • Feldene • Athrotec • Ceclor • Dilantin • Vioxx • Relafen • Celebrex • Levaquin • Depakote • Zantac • Tegretol • Provigil • Zithromax • Trileptal • Zyloprin • Clinoril • Phenytek Dangerous Drugs Severe drug reactions cause tens of thousands of patient deaths in this country each drugs) that have been linked to Stevens - Johnson Syndrome: • Anticonvulsants • Antibiotics • Nonsteroidal anti-inflammatory drugs (OTC and prescription) • Drugs with sulfa • Barbiturates • COX - 2 inhibitors • Ibuprofen • Acetaminophens • Allopurinol • Carbamazepine • Phenytoin • Bextra, which Pfizer removed from the market in 2005 because of the SJS risk it posed to users • Children's Advil or Motrin • Tylenol • Aldactone • Septra • Advil • Motrin • Avelox • Prilosec • Neurontin • Coreg • Feldene • Athrotec • Ceclor • Dilantin • Vioxx • Relafen • Celebrex • Levaquin • Depakote • Zantac • Tegretol • Provigil • Zithromax • Trileptal • Zyloprin • Clinoril • Phenytek Dangerous Drugs Severe drug reactions cause tens of thousands of patient deaths in this country each drugs (OTC and prescription) • Drugs with sulfa • Barbiturates • COX - 2 inhibitors • Ibuprofen • Acetaminophens • Allopurinol • Carbamazepine • Phenytoin • Bextra, which Pfizer removed from the market in 2005 because of the SJS risk it posed to users • Children's Advil or Motrin • Tylenol • Aldactone • Septra • Advil • Motrin • Avelox • Prilosec • Neurontin • Coreg • Feldene • Athrotec • Ceclor • Dilantin • Vioxx • Relafen • Celebrex • Levaquin • Depakote • Zantac • Tegretol • Provigil • Zithromax • Trileptal • Zyloprin • Clinoril • Phenytek Dangerous Drugs Severe drug reactions cause tens of thousands of patient deaths in this country each Drugs with sulfa • Barbiturates • COX - 2 inhibitors • Ibuprofen • Acetaminophens • Allopurinol • Carbamazepine • Phenytoin • Bextra, which Pfizer removed from the market in 2005 because of the SJS risk it posed to users • Children's Advil or Motrin • Tylenol • Aldactone • Septra • Advil • Motrin • Avelox • Prilosec • Neurontin • Coreg • Feldene • Athrotec • Ceclor • Dilantin • Vioxx • Relafen • Celebrex • Levaquin • Depakote • Zantac • Tegretol • Provigil • Zithromax • Trileptal • Zyloprin • Clinoril • Phenytek Dangerous Drugs Severe drug reactions cause tens of thousands of patient deaths in this country each Drugs Severe drug reactions cause tens of thousands of patient deaths in this country each year.

Prosecutors say that the adulterated drugs included generic versions of medications for epilepsy, acne, nerve pain, and an antibiotic.

Our pharmaceutical work puts us at the forefront of cutting edge issues, including preemption of medical device and prescription drug claims, the learned intermediary doctrine, comment k, market share liability, and brand name liability for generic use.

Among other things, the Act included elaborate provisions governing the mechanisms through which a potential generic manufacturer may obtain marketing approval for a drug that has been patented by another party.

Ratiopharm Inc. v. Canada (Attorney General) 2014 FC 502 Constitutional Law — Statutes — Trade Regulation Summary: Ratiopharm Inc. sold generic drugs in Canada, including ratio - salbutamol HFA («ratio HFA»), the generic equivalent of Ventolin HFA, a product manufactured by GlaxoSmithKline Inc. (GSK).

Pfizer sells about 600 generic medicines, including at least 40 that it made a deal for this week that it will sell in the United States; and Teva now reportedly gets about 30 % of its revenue from branded drugs.

We have represented clients in numerous other congressional investigations and oversight hearings, including a major internet services company in an investigation of its practices abroad, a chemical manufacturer in an investigation of the safety of its products, an insurance company in a hearing on the federal long term care insurance program, a financial services company in an investigation of credit card terms, and drug companies in investigations concerning such matters as payments to doctors, marketing practices, generic approvals, drug importation, and drug safety.

Medicare consists of several major benefits including Part A (hospitalization), Part B (office visits, outpatient care etc...), and prescription drugs (generic and non-generic).

The State Department recommends that anyone with a pre-existing medical condition, ranging from a heart problem to allergies, carry a letter from their physician that describes the condition, the treatment for it, and any prescription drugs that are being used, including their generic names.

This includes unlimited doctor's office visits, emergency room services, after - hours visits and generic drugs; all available with only a co-pay amount.

• Research new medications, including generic alternatives to brand name drugs, to provide helpful information to patients and healthcare personnel.

Students in this program will be instructed on how to function as an assistant to a licensed pharmacist including the standards of pharmacy ethics and law, microbiology, pharmaceutical and medical terminology, dosages, and both trade and generic names of drugs.

Knowledge of commonly used prescription drugs including brand / generic names available dosages, frequencies and indications.

May also work in the Inpatient Pharmacy, as needed.Required Minimum Position QualificationsEducation: High School diploma or equivalentLicense / Certification: Current Pharmacy Technician certificationNational certification from the Pharmacy Technician Certification Board required within six (6) months of obtaining positionPreferred Position QualificationsOne (1) year of outpatient Pharmacy Technician experienceBilingual (English / Spanish) Knowledge / Skills / AbilitiesExcellent written and verbal communication skills with people with diverse backgrounds and all levels with in the organization and in the community.Ability to create and foster a cooperative team work environment.Knowledge of pharmacy operations.Ability to perform accurate and timely data entry regarding medications.Basic computer skills.Knowledge of commonly used prescription drugs including brand / generic names available dosages, frequencies and indications.Meets Queen of the Valley Medical Center's Standards of Behavior including interpersonal communication and professional conduct expectations.Meditech familiarityAbility to have patience with sick and / or aging patients.